Understanding how HPV changes DNA repair in cancer cells
Rewiring of epigenetic DNA damage response pathways in HPV-induced cancer
This study is looking at how the human papilloma virus (HPV) changes the way anal cancer cells react to treatments that damage their DNA, with the goal of finding better ways to make radiation therapy work more effectively while protecting healthy cells.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10889905 on NIH RePORTER |
What this research studies
This research investigates how human papilloma virus (HPV) affects the way cancer cells respond to DNA damage, particularly in anal cancers. The team uses advanced techniques like CRISPR/Cas9 to identify specific genetic pathways that HPV alters, which may help cancer cells survive radiation treatment. By understanding these changes, the researchers aim to develop targeted therapies that can improve the effectiveness of radiotherapy while minimizing harm to healthy tissues. The work is guided by experienced mentors in radiation oncology, ensuring a strong clinical focus.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with HPV-positive anal cancer who are undergoing or considering radiotherapy.
Not a fit: Patients with HPV-negative anal cancer or those not receiving radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for anal cancer patients, improving their chances of recovery and reducing recurrence rates.
How similar studies have performed: Previous research has shown promising results in targeting epigenetic pathways in cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Goldstein, Michael — Johns Hopkins University
- Study coordinator: Goldstein, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.